Diindolylmethane (DIM) for Menopause

Verdict: No evidence DIM helps menopause symptoms

There is no clinical evidence that diindolylmethane (DIM) relieves menopause symptoms such as hot flashes, night sweats, sleep problems, or mood changes. Every human study to date measured only urinary estrogen-metabolite ratios, not actual symptoms, so DIM cannot be recommended for menopause.

U ⚫ U Unverified Taiwan Regulatory Restriction

🔬Why this grade7-layer evidence engine

This claim is graded Unverified because not a single trial has tested whether DIM eases menopausal symptoms. All five available human studies measured only urinary estrogen metabolites in non-symptomatic groups: cohorts of women on estradiol patches (PMID 40298801, n=1458) and premenopausal women (PMID 39578798, n=19294), plus tiny BRCA-carrier or breast-cancer-survivor trials (PMID 32458980, PMID 25613194, PMID 15623462, each n<25). The two large cohorts came from the company selling the hormone test, and the 2015 BRCA trial (PMID 25613194) failed its primary endpoint (p=0.35).

A shifted estrogen-metabolite ratio is an unvalidated biomarker, not proof of symptom relief. Worse, the 2025 study (PMID 40298801) found DIM pushed patch-delivered estradiol toward the 2-hydroxylation pathway, lowering active estrogen — the opposite of what menopause treatment aims for, suggesting DIM could blunt hormone therapy.

Authorities reinforce the caution. Mayo Clinic, citing 2023 menopause guidelines, states "no supplements had been proved effective" for hot flashes, and a relevant specialty society stance is against. The EU classifies purified DIM as an unauthorized Novel Food (not legally sold as a supplement), and even Health Canada — which permits DIM only for estrogen-metabolism balance — lists hot flashes, night sweats, and vaginal dryness as reasons to consult a doctor before use. A drug-interaction flag (notably tamoxifen) adds further reason for caution.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.39
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
U · Taiwan Regulatory Restriction
Confidence
85%
Highly consistent evidence
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L11 AI re-checkIndependent read
0.20
L5 Clinical bodiesAuthoritative stance
0.31
L2 PubMedPrimary literature
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.393
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — D 級條件未達 (需 E1-E3 negative;實際 E6)
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

The impact of 3,3'-diindolylmethane on estradiol and estrogen metabolism in postmenopausal women using a transdermal estradiol patch
PMID: 40298801 2025 Cohort n = 1,458
Finding: DIM users showed statistically significant alterations across 7 of 10 urinary estrogen metabolites vs non-users (multivariable regression P=0.002-0.02; overall profile P<0.001) — lower estrone/estriol, higher 2-hydroxyestrone and 2-hydroxyestradiol; suggests DIM shifts patch-delivered estradiol toward 2-hydroxylation pathway
⚠️ Industry-funded
View on PubMed
Exploring the impact of 3,3'-diindolylmethane on the urinary estrogen profile of premenopausal women
PMID: 39578798 2024 Cohort n = 19,294
Finding: DIM users had significantly different concentrations in almost every urinary estrogen metabolite vs non-users (p<0.001 for all except 2-methoxyestrone); 2-OHE1:16-OHE1 ratio increased significantly in before/after analysis (p<0.001)
🟠 Limited quality ⚠️ Industry-funded
View on PubMed
3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial
PMID: 32458980 2020 RCT (open-label) n = 23
Finding: FGT decreased 2.8 to 2.65 (P=0.031); estradiol decreased 159 to 102 pmol/L (P=0.01); testosterone decreased 0.42 to 0.31 pmol/L (P=0.007). Median age 47y, 78% postmenopausal but not stratified
🟠 Limited quality Effect size: [object Object]
View on PubMed
The effect of oral 3,3'-diindolylmethane supplementation on the 2:16alpha-OHE ratio in BRCA1 mutation carriers
PMID: 25613194 2015 RCT (open-label) n = 20
Finding: Ratio increased from 2.4 to 3.0 but NOT statistically significant (P=0.35); authors concluded short DIM intervention did not significantly raise the 2:16 ratio. Menopausal status not specified
🟠 Limited quality Effect size: [object Object]
View on PubMed
Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer
PMID: 15623462 2004 RCT (double-blind) n = 19
Finding: DIM significantly increased urinary 2-OHE1 (P=0.020) and 2:16-alpha-OHE1 ratio vs placebo; small pilot, NOT measuring menopause symptoms — relevant only as estrogen-metabolism mechanism evidence, in tamoxifen-treated breast cancer survivors
🟠 Limited quality Academic
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
3,3'-DIINDOLYLMETHANE source↗
L4b EU EFSA
Against
Purified, synthetic 3,3'-diindolylmethane powder in supplement form is considered novel... 3,3'-diindolylmethane powder has been classified as a 'Novel Food' because it had not been consumed to a significant degree by humans in the UK or the European Union before May 15, 1997. It has not been granted authorization for sale as a food supplement. source↗
L4e WHO
Supportive
3,3'-Diindolylmethane (DIM). CAS 1968-05-4. Source materials: Brassica oleracea var. botrytis (cauliflower), var. capitata (cabbage), var. gemmifera (Brussels sprouts), var. italica (broccoli) — whole plant. Schedule 1, Item 2 (isolate). Approved Use(s) or Purpose(s): Source of/Provides antioxidants that help fight/protect cells against/reduce the oxidative effects of (or oxidative damage cause… source↗
L5a NIH Office of Dietary Supplements
Cautious
L5e Specialty Society (condition-mapped)
Against
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-menopause-INT-diindolylmethane-001 繁體中文版 →